FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097566261> ?p ?o ?g. }

• W3097566261 abstract "Objective: Antipsychotic drugs are widely used for treating patients with first episode of psychosis, targeting threshold psychotic symptoms. The clinical high risk of psychosis is characterized as subthreshold psychotic symptoms and it is unclear whether they can also benefit from antipsychotic drugs treatment. This study attempted to determine whether initiating antipsychotic drugs treatment in the clinical high risk of psychosis phase was superior to initiating antipsychotic drugs treatment in the first episode of psychosis phase, after the 2-year symptomatic and functional outcomes. Method: Drawing on 517 individuals with clinical high risk of psychosis from the ShangHai At Risk for Psychosis program, we identified 105 patients who converted to first episode of psychosis within the following 2 years. Patients who initiated antipsychotic drugs while at clinical high risk of psychosis (CHR_AP; n = 70) were compared with those who initiated antipsychotic drugs during a first episode of psychosis (FEP_AP; n = 35). Summary scores on positive symptoms and the global function scores at baseline and at 2 months, 1 year and 2 years of follow-up were analyzed to evaluate outcomes. Results: The CHR_AP and FEP_AP groups were not different in the severity of positive symptoms and functioning at baseline. However, the CHR_AP group exhibited significantly more serious negative symptoms and total symptoms than the FEP_AP group. Both groups exhibited a significant reduction in positive symptoms and function ( p < 0.001). Repeated-measures analysis of variance revealed group by time interaction for symptomatic ( F = 3.196, df = 3, p = 0.024) and functional scores ( F = 7.306, df = 3, p < 0.001). The FEP_AP group showed higher remission rates than the CHR_AP group (χ 2 = 22.270, p < 0.001). Compared to initiating antipsychotic drug treatments in the clinical high risk of psychosis state, initiating antipsychotic drugs treatments in the first episode of psychosis state predicted remission in a regression model for FEP_AP (odds ratio = 5.567, 95% confidence interval = [1.783, 17.383], p = 0.003). Conclusion: For clinical high risk of psychosis, antipsychotic drugs might be not the first choice in terms of long-term remission, which is more reasonable to use at the first episode of psychosis phase." @default.
• W3097566261 created "2020-11-09" @default.
• W3097566261 creator A5003728286 @default.
• W3097566261 creator A5012276279 @default.
• W3097566261 creator A5016774224 @default.
• W3097566261 creator A5019444350 @default.
• W3097566261 creator A5036318674 @default.
• W3097566261 creator A5054133322 @default.
• W3097566261 creator A5058219030 @default.
• W3097566261 creator A5058226962 @default.
• W3097566261 creator A5072024833 @default.
• W3097566261 creator A5084907875 @default.
• W3097566261 date "2020-11-03" @default.
• W3097566261 modified "2023-10-10" @default.
• W3097566261 title "When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?" @default.
• W3097566261 cites W1834366268 @default.
• W3097566261 cites W1963587466 @default.
• W3097566261 cites W1967674108 @default.
• W3097566261 cites W1990043440 @default.
• W3097566261 cites W1999757758 @default.
• W3097566261 cites W2024581069 @default.
• W3097566261 cites W2053821113 @default.
• W3097566261 cites W2057883114 @default.
• W3097566261 cites W2076931387 @default.
• W3097566261 cites W2103926490 @default.
• W3097566261 cites W2107261104 @default.
• W3097566261 cites W2114311139 @default.
• W3097566261 cites W2121366540 @default.
• W3097566261 cites W2135392214 @default.
• W3097566261 cites W2139095930 @default.
• W3097566261 cites W2139685490 @default.
• W3097566261 cites W2154056444 @default.
• W3097566261 cites W2165887956 @default.
• W3097566261 cites W2318863846 @default.
• W3097566261 cites W2535497867 @default.
• W3097566261 cites W2721504914 @default.
• W3097566261 cites W2766894874 @default.
• W3097566261 cites W2768518012 @default.
• W3097566261 cites W2794642496 @default.
• W3097566261 cites W2799778639 @default.
• W3097566261 cites W2801950099 @default.
• W3097566261 cites W2805985567 @default.
• W3097566261 cites W2810094360 @default.
• W3097566261 cites W2890862698 @default.
• W3097566261 cites W2896518676 @default.
• W3097566261 cites W2899203206 @default.
• W3097566261 cites W2970471631 @default.
• W3097566261 cites W2973265280 @default.
• W3097566261 cites W2975990791 @default.
• W3097566261 cites W2985054930 @default.
• W3097566261 cites W2995360999 @default.
• W3097566261 cites W2998018164 @default.
• W3097566261 cites W3017370768 @default.
• W3097566261 cites W3023277950 @default.
• W3097566261 cites W4294354524 @default.
• W3097566261 cites W58010879 @default.
• W3097566261 doi "https://doi.org/10.1177/0004867420969810" @default.
• W3097566261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33143440" @default.
• W3097566261 hasPublicationYear "2020" @default.
• W3097566261 type Work @default.
• W3097566261 sameAs 3097566261 @default.
• W3097566261 citedByCount "6" @default.
• W3097566261 countsByYear W30975662612021 @default.
• W3097566261 countsByYear W30975662612022 @default.
• W3097566261 crossrefType "journal-article" @default.
• W3097566261 hasAuthorship W3097566261A5003728286 @default.
• W3097566261 hasAuthorship W3097566261A5012276279 @default.
• W3097566261 hasAuthorship W3097566261A5016774224 @default.
• W3097566261 hasAuthorship W3097566261A5019444350 @default.
• W3097566261 hasAuthorship W3097566261A5036318674 @default.
• W3097566261 hasAuthorship W3097566261A5054133322 @default.
• W3097566261 hasAuthorship W3097566261A5058219030 @default.
• W3097566261 hasAuthorship W3097566261A5058226962 @default.
• W3097566261 hasAuthorship W3097566261A5072024833 @default.
• W3097566261 hasAuthorship W3097566261A5084907875 @default.
• W3097566261 hasConcept C118552586 @default.
• W3097566261 hasConcept C126322002 @default.
• W3097566261 hasConcept C15744967 @default.
• W3097566261 hasConcept C2776412080 @default.
• W3097566261 hasConcept C2779727114 @default.
• W3097566261 hasConcept C2780494398 @default.
• W3097566261 hasConcept C71924100 @default.
• W3097566261 hasConceptScore W3097566261C118552586 @default.
• W3097566261 hasConceptScore W3097566261C126322002 @default.
• W3097566261 hasConceptScore W3097566261C15744967 @default.
• W3097566261 hasConceptScore W3097566261C2776412080 @default.
• W3097566261 hasConceptScore W3097566261C2779727114 @default.
• W3097566261 hasConceptScore W3097566261C2780494398 @default.
• W3097566261 hasConceptScore W3097566261C71924100 @default.
• W3097566261 hasFunder F4320321001 @default.
• W3097566261 hasFunder F4320321540 @default.
• W3097566261 hasFunder F4320321885 @default.
• W3097566261 hasFunder F4320330350 @default.
• W3097566261 hasLocation W30975662611 @default.
• W3097566261 hasOpenAccess W3097566261 @default.
• W3097566261 hasPrimaryLocation W30975662611 @default.
• W3097566261 hasRelatedWork W12422011 @default.
• W3097566261 hasRelatedWork W13821031 @default.
• W3097566261 hasRelatedWork W2103198 @default.
• W3097566261 hasRelatedWork W2286111 @default.

• next